Key result
ACURATE neo2 TAVI shows ~3% 30-day mortality in severe symptomatic AS.
Why the study?
TAVI has become standard treatment for elderly patients with symptomatic severe aortic valve stenosis, but clinical and hemodynamic outcomes with the ACURATE neo2 valve require evaluation.
Does transcatheter aortic valve implantation with the ACURATE neo2 valve improve clinical and hemodynamic outcomes in elderly patients with symptomatic severe aortic valve stenosis?
Cohort (n=120)
Yes
Does transcatheter aortic valve implantation with the ACURATE neo2 valve improve clinical and hemodynamic outcomes in elderly patients with symptomatic severe aortic valve stenosis?
The ACURATE neo2 valve system demonstrates favorable 1-year safety, low mortality, and excellent hemodynamic performance in elderly patients with severe aortic stenosis.
No takes yet. Share an insight, caveat, or question.
Supports ACURATE neo2 feasibility in real-world TAVI; observational data leave comparative efficacy open to randomized trials.
Möllmann et al. (2021) conducted a cohort in severe symptomatic aortic stenosis (n=120). ACURATE neo2 valve system was evaluated on 30-day all-cause mortality. Transcatheter aortic valve implantation with the ACURATE neo2 valve system resulted in a 30-day all-cause mortality rate of 3.3% in patients with severe symptomatic aortic stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: